No enrichment was seen with alterations in other clinically relevant biomarkers such as EGFR, ERBB2, RET, ALK or MET. Supplementary Table 9 summarises results for all genes tested for co-occurrence, providing insight into the genomic landscape of NTRK gene fusion-positive cancers. This evidence concerns the gene RET and cancer.